REGM.F Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.00 |
| 52 Week High | HK$4.60 |
| 52 Week Low | HK$2.01 |
| Beta | 0.55 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| REGM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | 2.2% | 1.7% |
| 1Y | n/a | 5.8% | 26.0% |
Return vs Industry: Insufficient data to determine how REGM.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how REGM.F performed against the US Market.
Price Volatility
| REGM.F volatility | |
|---|---|
| REGM.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: REGM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine REGM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,615 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
RemeGen Co., Ltd. Fundamentals Summary
| REGM.F fundamental statistics | |
|---|---|
| Market cap | US$3.20b |
| Earnings (TTM) | -US$212.32m |
| Revenue (TTM) | US$172.07m |
12.5x
P/S Ratio-10.1x
P/E RatioIs REGM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGM.F income statement (TTM) | |
|---|---|
| Revenue | CN¥1.25b |
| Cost of Revenue | CN¥306.53m |
| Gross Profit | CN¥938.62m |
| Other Expenses | CN¥2.47b |
| Earnings | -CN¥1.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.86 |
| Gross Margin | 75.38% |
| Net Profit Margin | -123.39% |
| Debt/Equity Ratio | 53.2% |
How did REGM.F perform over the long term?
See historical performance and comparison